A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

← catalyst calendar

NCT06682988

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.

Phase

Phase 2

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

110estimated

Sites

Countries

Australia, Belgium, France +5

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-05-28

actual

When the study began enrolling

Primary completion

Jul 2026

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Apr 2028

estimated

The whole study's end, after follow-up

First posted

2024-11-12

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-05-26

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Advanced High-Grade Epithelial Ovarian Cancer
Primary Peritoneal Cancer
Fallopian Tube Cancers

Intervention

Drug: Mirvetuximab Soravtansine — also filed as MIRV, IMGN853

Primary outcomes

what the primary-completion date above is the date OF

Randomized Phase 2 Cohort: Percentage of Participants with Grade >= 2 Treatment-Emergent Corneal Adverse Events (AEs)